Search

Verastem Expected To Rock Upcoming Conferences

Verastem to Present at Upcoming Conferences CAMBRIDGE, MA – June 10 — Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows: 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 3:30 p.m. ET at The InterContinental Hotel in Boston, MA ROTH Healthcare Corporate Access Day on Tuesday, June 24, 2014 at the Dorchester Hotel in London, UK 9th Annual JMP Securities Healthcare Conference on Wednesday June 25, 2014 at 1:30 p.m. ET at the Westin New York Grand Central in New York, NY Webcasts of the Wells Fargo and JMP Securities presentations can be accessed by visiting the investors section of the Company’s website at www.verastem.com. Replays will be archived on the Verastem website for 90 day s following the presentation dates.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com. Forward-looking statements: Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. Ho wever, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Verastem, Inc. Brian Sullivan, 617-252-9314 bsullivan@verastem.com

Posted in News | Comments Off on Verastem Expected To Rock Upcoming Conferences

Mesothelioma Stem Cells Targeted By New Drug

Verastem to Present New Data at the 12th International Mesothelioma Interest Group Conference NEEDHAM, MA – Oct. 8 — Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it will present new data at the 12th International Mesothelioma Interest Group (iMig) Conference being held October 22-24, 2014, in Cape Town, South Africa. Investigators and members of the Verastem leadership team will give oral presentations discussing the Company’s development programs targeting cancer stem cells (CSC’s) with a focus on lead inhibitor VS-6063 (defactinib). VS-6063 targets CSC’s, a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy, and can mediate tumor recurrence both locally and at metastatic sites. VS-6063 targets CSC’s through the potent inhibition of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed its critical role in CSC survival and disease progression. Professor Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital and principal investigator of Verastem’s ongoing “Window of Opportunity” study evaluating the effect of single agent VS-6063 on specific biomarkers in patients with mesothelioma undergoing surgery, will present data from the ongoing study. “We are honored to have been selected for several presentations at this year’s iMig Conference and to participate with other industry and medical leaders in the fight against mesothelioma,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “These presentations, along with our ongoing development efforts with our lead candidate VS-6063, which is currently being studied in the global, registration-directed COMMAND study for patients with mesothelioma, demonstrate our commitment to growing the body of knowledge surrounding the t reatment of this highly aggressive form of cancer.” The schedule for the presentations is as follows: iMig Special Keynote Lecture: “Cancer Stem Cells as Target Pathways” Presenter: Robert Weinberg, Ph.D., Whitehead Institute and Verastem scientific cofounder and chair of the Scientific Advisory Board Presentation Title: “Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM” Presenter: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy” Presenter: Paul Baas, M.D., Ph. D., Department of Thoracic Oncology,The Netherlands Cancer Institute Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS-5584 Exhibit Synergisti c Anticancer Activity in Preclinical Models of Mesothelioma” Presenter: Mitchell Keegan, Ph.D., Vice President, Development, Verastem

About Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is an aggressive form of cancer that occurs in the mesothelium, the thin layer of tissue that covers the lungs. Mesothelioma is associated with exposure to asbestos in most cases. According to the World Health Organization, there are a total of 59,000 cases of mesothelioma worldwide each year. Most mesotheliomas begin as one or more nodules that progressively grow to form a solid coating of tumor surrounding the lung leading to eventual suffocation and death. A high percentage of mesotheliomas contain cancer stem cells which are generally resistant to the currently available treatment options for mesothelioma.

About VS-6063

VS-6063 (Defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhe sion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research by Robert Weinberg, Ph.D., scientific cofounder and chair of Verastem’s Scientific Advisory Board, and Verastem has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, and a trial in patients with Kras-mutated non-small cell lung cancer. VS-6063 has been granted orphan drug designation in the U.S. and EU for use in mesothelioma.

About VS-5584

VS-5584 is an orally available compound that has demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2. In preclinical studies, VS-5584 has been shown to reduce the percentage of cancer stem cells and induce tumor regression in chemotherapy-resistant models. Verastem is currently conducting a Phase 1 dose escalation trial of VS-5584 in patients with advanced solid tumors and lymphomas.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com. Forward-looking statements: This press release includes forward-looking statements about the Company’s strategy, future plans and prospects, including statements regar ding the development of the Company’s compounds, including VS-6063, or defactinib and VS-5584 and the Company’s FAK inhibition and PI3K/mTOR programs generally, the timeline for clinical development and regulatory approval of the Company’s compounds, the expected timing for the reporting of data from ongoing trials, and the structure of the Company’s planned or pending clinical trials. The words “anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks an d uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Company’s compounds and preliminary data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when we expect it to be, that enrollment of clinical trials may take longer than expected, that the Company will be unable to successfully complete the clinical development of its compounds, including VS-6063 and VS-5584, that the development of the Company’s compounds will take longer or cost more than planned, and that the Company’s compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 a nd in any subsequent SEC filings. The forward-looking statements contained in this press release reflect the Company’s current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements. Verastem, Inc. Brian Sullivan, 617-252-9314 bsullivan@verastem.com

Posted in News | Comments Off on Mesothelioma Stem Cells Targeted By New Drug

Less Invasive Treatment for Pleural Mesothelioma

Researchers Find Less Invasive Treatment for Pleural Mesothelioma Shortens Hospital Stays, Reduces Complications, Baron and Budd Reports Talc Pleurodesis Offers Several Benefits Over Video-Assisted Method of Reducing Fluid Buildup in Lungs DALLAS – July 10 – Researchers in the United Kingdom have found that a procedure that uses talc to help seal the lining of the lungs in patients suffering from pleural mesothelioma is superior to a video-assisted surgical procedure in reducing hospital stays and the occurrence of complications, the mesothelioma law firm of Baron and Budd reports. The results of the research were published in the June 14 issue of The Lancet, a British medical journal. (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60418-9/abstract) A method of treatment known as Video-Assisted Thoracoscopic Partial Pleurectomy (VATPP) is used in some instances in order to reduce the amount of fluid buildup that takes place between the layers of lung lining in pleural mesothelioma patients. However, the researchers showed that a different procedure, one known as talc pleurodesis, can be significantly more effective. The talc pleurodesis procedure involves draining lung lining of fluid and then using talc to seal the pleural layers. The team studied 175 pleural mesothelioma patients between 2003 and 2012 who had a buildup of fluid (also known as pleural effusions) in the lungs. Of those patients, 88 had the talc pleurodesis procedure and 87 had the VATPP procedure performed. According to the study, 24 of the VATPP patients suffered surgical complications, while complications occurred in only 10 of those patients who had the talc pleurodesis procedure performed. In addition, the study showed that VATPP patients had more air leaks in their lungs and also suffered other respiratory complications. The research a lso showed that VATPP patients stayed in the hospital two times longer than talc pleurodesis patients; seven days versus three days. The survival rate of those treated with the two procedures was relatively negligible, however; 52 percent of VATPP patients survived one year after the procedure while 57 of the talc pleurodesis patients had survived. “This study is significant in the fact that it could lead to more widespread acceptance of the talc pleurodesis method, which could make pleural mesothelioma patients significantly more comfortable while undergoing treatment,” said Russell Budd, managing director of mesothelioma law firm Baron and Budd. “Taking the findings into account, as well as considering the fact that talc pleurodesis is less expensive than VATPP, it appears that talc pleurodesis is the preferable option.” There is a chance that you or a loved one who suffers from mesothelioma m ay be able to take legal action against those parties that caused the exposure to asbestos that led to the development of the disease. If you would like to learn more, call the mesothelioma law firm of Baron and Budd at 1-866-855-1229 or visit our website at http://www.fightmesothelioma.com. Contact Information Amanda Billo Baron & Budd http://baronandbudd.com +1 (214) 991-1051

Posted in News | Comments Off on Less Invasive Treatment for Pleural Mesothelioma

Mesothelioma Growth Slowed by Curcumin and Peptides

Study Finds Mesothelioma Growth Slowed by Curcumin and Peptides, According to Surviving Mesothelioma Cancer researchers in Ohio and Germany have demonstrated that mesothelioma cells can be destroyed in the lab with a combination of components, one of which comes from a popular spice. Raleigh, NC – September 26 –  New research appears to support the cancer-fighting power of curcumin, a polyphenol that is the primary component in the Asian spice, turmeric. Surviving Mesothelioma has just posted the full story on its website. Click here to read it now. Doctors at the Case Comprehensive Cancer Center in Ohio and the Georg-Speyer-Haus Institute for Biomedical Research in Germany treated mesothelioma cells with a combination of curcumin and peptides extracted from PIAS3, a molecule shown to neutralize a cancer-triggering protein. “Our interest for the future is that we want to find better, more simple ways to increase intracellular levels of PIAS3 for malign ant mesothelioma through the use of synthetic PIAS3 peptide or curcumin analogs,” says Dr. Afshin Dowlati, a professor at Case Western Reserve School of Medicine. With the help of curcumin, PIAS3 neutralized the effects of STAT3, a signaling protein linked to the start and growth of mesothelioma and other cancers. The findings appear in Clinical Cancer Research. “These findings add to the growing body of research suggesting that this simple spice could hold important clues about how we can better combat mesothelioma and other intractable cancers,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. To learn more about curcumin and its links to cancer, see Component in Spice May Help Slow Mesothelioma Growth, now available on the Surviving Mesothelioma website. Dabir, S et al, “Low PIAS3 Expression in Malignant mesothelioma is associated with increased STAT3 activation and poor patient survival”, August 14, 2014, Clinical Cancer Research, Epub ahead of print, http://clincancerres.aacrjournals.org/content/early/2014/08/14/1078-0432.CCR-14-1233.abstract For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions. Contact Information Michael Ellis Cancer Monthy http://www.survivingmesothelioma.com +1 (919) 570-8595

Posted in News | Comments Off on Mesothelioma Growth Slowed by Curcumin and Peptides

New Medical Radiation Treatment Gets Funding

Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel. Claremont, CA – September 27 – Synedgen announced today the award of a competitive Small Business Innovation Research (SBIR) Phase I contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment for radiation proctitis, a condition that causes painful tissue damage to the lining of the gastrointestinal (GI) tract caused by radiotherapy. With this award, Synedgen will complete efficacy studies for its proprietary formulation of it’s polymer-based pharmaceutical, SY513, to alleviate radiation proctitis following medical radiotherapy often used to treat prostate cancer, ovarian cancer and tumors originating in the pelvic region. Radi ation proctitis impacts as much as 75% of patients treated by radiotherapy in the lower bowel area and can cause both short term and chronic pain. In some cases, acute radiation proctitis is so serious that the intensity of the radiotherapy has to be reduced, ultimately jeopardizing the patient’s prognosis for successful cancer treatment. Synedgen has developed formulations of its proprietary high molecular weight polymer therapeutics to reduce radiation or chemical damage to the oral cavity and the entire length of the GI tract. Synedgen’s orally delivered GI treatments have shown a remarkable ability to reduce local and systemic inflammation, reduce cell death and improve tissue regeneration associated with radiation-induced damage in the large and small intestines in animal models that mimic conditions seen in human therapies. “This award helps further expand our growing portfolio of oncology supportive care products. Our surface-active polymers have broad mechanism of ac tion, which are designed to reduce inflammation and tissue damage due to chemical or radiation damage. Based on our previous positive research findings, we anticipate this formulation and delivery directly to the affected area will limit the damage of radiation therapy, and allow more aggressive treatment of prostate and other pelvic cancers that are currently limited by radiation proctitis,” stated Synedgen president Shenda Baker. “Acute radiation-induced injury to the GI mucosa occurs in virtually all patients undergoing radiation therapy. Clearly, there is a need for new agents to reduce the short and long-term side effects of radiotherapy and minimize tissue damage. We are optimistic that this research will result in improved survival of and quality of life for cancer patients,” added CEO William Wiesmann M.D. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services under Contract No. HHSN261201400011C. This NCI is fully funding $196,707 for the specific project costs under the contract. About Synedgen Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary, mucosal and gastrointestinal surfaces. Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com. Contact Information Nicole Draghic Synedgen Inc. http://www.synedgen.com +1 (301) 428-9818 Ext: 250

Posted in News | Comments Off on New Medical Radiation Treatment Gets Funding

Asbestos-contaminated Forest Doesn’t Burn

EPA Finds Asbestos-contaminated Libby Forest Libby, Mont – A new research says timber harvesting can effectively be used as a potential remedy for a swath of asbestos-filled Libby forest, where vermiculite mining for decades resulted in extensive pollution. The 35000 acre forest is fully contaminated and so far has escaped being burned. Asbestos-linked diseases have killed approximately 400 individuals and sickened more than 1750 people in Libby, Montana since the W.R. Grace Vermiculite mining released asbestos fibers into the air of the mountain town, which is said to be the country’s most lethal superfund site. Thus far, the United States Environmental Protection Agency (EPA) has spent around $370 M in efforts to cleanup asbestos-tainted soil and building materials from there. The Vermiculite mine, which is no longer functional, produced 2 M tons of asbestos-containing ore yearly and engaged 200 individuals when it was running in full capacity. This vermiculite was exported to countries all over the world for making insulation. Just as they pierced into the human lungs’ pleural lining, microscopic asbestos fibers also penetrated the barks of Douglas fir, lodgepole pine, larch and ponderosa in the Libby forests. A Montana University study in year 2004 measured as well as confirmed concentrations of asbestos in trees close to the Vermiculite mine site. However, the Environmental Protection Agency, which determined Libby as a dangerous Superfund site in year 2002 and made a public health emergency declaration in year 2009, had been busy with its attempts to clean up homes, schools, playgrounds and businesses. A remediation program for the contaminated forest is not in place still. It may take several years for any such efforts to begin. In the mean time, residents regularly cut logs from the forest and therefore a fire could be disastrous. In recent times, 2 remediation firms – Missoula (Mont)-based Envirocon and Po rtland (OR)-based Beck Group – won contract from the Lincoln Port Authority for drafting a feasibility research to develop a remediation program for the forest located 6 miles outside the city center of Libby. Asbestos concentrations in this site are still the highest. No evidence is there to ensure that the trees’ meat has been contaminated by the fibers of asbestos. However, according to the study reports, if harvesting as well as debarking could be attained in a safe and financially feasible manner, the sale of the timber would be profitable. Remedial measures may take 10 or more years to complete, according to the project team.

Posted in News | Comments Off on Asbestos-contaminated Forest Doesn’t Burn

Up-to-Date Information for Mesothelioma Patients

MesotheliomaMedical.com Provides Up-to-Date Information for Mesothelioma Patients with Newly Designed Site Mesothelioma patients seeking information about treatments, support resources and mesothelioma treatment centers can find up-to-date information on the newly designed site, mesotheliomamedical.com. Legal information is also available on the site. Over 10,000 people worldwide are diagnosed with mesothelioma or other asbestos-related conditions each year, 3,000 in the US alone. Houston, Texas – June 07, 2011 – Mesotheliomamedical.com newly designed site provides up-to-date information to mesothelioma patients and families regarding diagnosis, treatment options, mesothelioma treatment centers and psychological support. The site is an online directory with answers to mesothelioma patientsâ?? many questions. There are also free resources, such as informational DVDs, for mesothelioma patients and families available through the site. Mesothelioma is an agg ressive, deadly cancer afflicting the lining of the lungs, abdomen, or heart cavity. The most common type of mesothelioma diagnosed is pleural, which originates in the lining of the lungs. The disease is diagnosed using several methods and tests. Pleural mesothelioma is not caused by smoking. It is most commonly caused by exposure to asbestos, a particle used in certain industries such as the automotive industry, railroad, power plant, mining industry, and in the Navy. In fact, it has been reported that approximately 30 percent of mesothelioma cases occur in people exposed to asbestos during their military service. Asbestos was used as an insulator for certain products and parts people were often exposed to on a daily basis because of the productâ??s unique ability to resist heat. It has been discovered that mesothelioma symptoms often begin 30-50 years after exposure to asbestos. Common symptoms of pleural mesothelioma are chest congestion, coughing, fever and weight loss. Each type of mesothelioma presents different symptoms. At times, patients confuse pleural mesothelioma symptoms with those of pneumonia. This cancer has affected people as young as 18 years old, but is more common in people over age 60. Family members have also had a mesothelioma diagnosis after secondary exposure to asbestos from a loved one who worked in an industry with high asbestos use. Family members are often exposed through contact with the clothing of a loved one, which they inhale. Mesotheliomamedical.com offers informational DVDs; mesothelioma support gear; connection with Col. Ted Frandsen, a veteran who offers support to mesothelioma patients exposed to asbestos during their time in service; nutrition advice; and other free resources for patients and families. The site offers advice to patients and families who are in search of resources and support. Families seeking information about financial resources to help pay for medical bills arising from a me sothelioma diagnosis can ref er to http://www.mesotheliomamedical.com. There is information about asbestos lawyers and financial compensation for mesothelioma patients and families to help ensure a stable financial future. About MesotheliomaMedical.com Mesotheliomamedical.com is a site created by attorneys with years of experience helping mesothelioma patients and families and not only provides legal information, but medical mesothelioma options as well. For mesothelioma patients and families interested in contacting an attorney, visit mesotheliomamedical.com. The site can answer medical questions, including those regarding alternative mesothelioma treatment options, clinical trials, and those on how it is diagnosed. Learn more about how this site can help you and your family at: http://www.mesotheliomam edical.com/ Written By Jennifer Zambito Contact Rod DeLlano Danziger & DeLlano 1(800)310-2970

Posted in News | Comments Off on Up-to-Date Information for Mesothelioma Patients

Verastem Expected To Rock Upcoming Conferences

Verastem to Present at Upcoming Conferences CAMBRIDGE, MA – June 10 — Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows: 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 3:30 p.m. ET at The InterContinental Hotel in Boston, MA ROTH Healthcare Corporate Access Day on Tuesday, June 24, 2014 at the Dorchester Hotel in London, UK 9th Annual JMP Securities Healthcare Conference on Wednesday June 25, 2014 at 1:30 p.m. ET at the Westin New York Grand Central in New York, NY Webcasts of the Wells Fargo and JMP Securities presentations can be accessed by visiting the investors section of the Company’s website at www.verastem.com. Replays will be archived on the Verastem website for 90 day s following the presentation dates.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com. Forward-looking statements: Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. Ho wever, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Verastem, Inc. Brian Sullivan, 617-252-9314 bsullivan@verastem.com

Posted in News | Comments Off on Verastem Expected To Rock Upcoming Conferences

Mesothelioma Stem Cells Targeted By New Drug

Verastem to Present New Data at the 12th International Mesothelioma Interest Group Conference NEEDHAM, MA – Oct. 8 — Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it will present new data at the 12th International Mesothelioma Interest Group (iMig) Conference being held October 22-24, 2014, in Cape Town, South Africa. Investigators and members of the Verastem leadership team will give oral presentations discussing the Company’s development programs targeting cancer stem cells (CSC’s) with a focus on lead inhibitor VS-6063 (defactinib). VS-6063 targets CSC’s, a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy, and can mediate tumor recurrence both locally and at metastatic sites. VS-6063 targets CSC’s through the potent inhibition of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed its critical role in CSC survival and disease progression. Professor Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital and principal investigator of Verastem’s ongoing “Window of Opportunity” study evaluating the effect of single agent VS-6063 on specific biomarkers in patients with mesothelioma undergoing surgery, will present data from the ongoing study. “We are honored to have been selected for several presentations at this year’s iMig Conference and to participate with other industry and medical leaders in the fight against mesothelioma,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “These presentations, along with our ongoing development efforts with our lead candidate VS-6063, which is currently being studied in the global, registration-directed COMMAND study for patients with mesothelioma, demonstrate our commitment to growing the body of knowledge surrounding the t reatment of this highly aggressive form of cancer.” The schedule for the presentations is as follows: iMig Special Keynote Lecture: “Cancer Stem Cells as Target Pathways” Presenter: Robert Weinberg, Ph.D., Whitehead Institute and Verastem scientific cofounder and chair of the Scientific Advisory Board Presentation Title: “Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM” Presenter: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy” Presenter: Paul Baas, M.D., Ph. D., Department of Thoracic Oncology,The Netherlands Cancer Institute Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS-5584 Exhibit Synergisti c Anticancer Activity in Preclinical Models of Mesothelioma” Presenter: Mitchell Keegan, Ph.D., Vice President, Development, Verastem

About Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is an aggressive form of cancer that occurs in the mesothelium, the thin layer of tissue that covers the lungs. Mesothelioma is associated with exposure to asbestos in most cases. According to the World Health Organization, there are a total of 59,000 cases of mesothelioma worldwide each year. Most mesotheliomas begin as one or more nodules that progressively grow to form a solid coating of tumor surrounding the lung leading to eventual suffocation and death. A high percentage of mesotheliomas contain cancer stem cells which are generally resistant to the currently available treatment options for mesothelioma.

About VS-6063

VS-6063 (Defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhe sion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research by Robert Weinberg, Ph.D., scientific cofounder and chair of Verastem’s Scientific Advisory Board, and Verastem has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, and a trial in patients with Kras-mutated non-small cell lung cancer. VS-6063 has been granted orphan drug designation in the U.S. and EU for use in mesothelioma.

About VS-5584

VS-5584 is an orally available compound that has demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2. In preclinical studies, VS-5584 has been shown to reduce the percentage of cancer stem cells and induce tumor regression in chemotherapy-resistant models. Verastem is currently conducting a Phase 1 dose escalation trial of VS-5584 in patients with advanced solid tumors and lymphomas.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com. Forward-looking statements: This press release includes forward-looking statements about the Company’s strategy, future plans and prospects, including statements regar ding the development of the Company’s compounds, including VS-6063, or defactinib and VS-5584 and the Company’s FAK inhibition and PI3K/mTOR programs generally, the timeline for clinical development and regulatory approval of the Company’s compounds, the expected timing for the reporting of data from ongoing trials, and the structure of the Company’s planned or pending clinical trials. The words “anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks an d uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Company’s compounds and preliminary data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when we expect it to be, that enrollment of clinical trials may take longer than expected, that the Company will be unable to successfully complete the clinical development of its compounds, including VS-6063 and VS-5584, that the development of the Company’s compounds will take longer or cost more than planned, and that the Company’s compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 a nd in any subsequent SEC filings. The forward-looking statements contained in this press release reflect the Company’s current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements. Verastem, Inc. Brian Sullivan, 617-252-9314 bsullivan@verastem.com

Posted in News | Comments Off on Mesothelioma Stem Cells Targeted By New Drug

Less Invasive Treatment for Pleural Mesothelioma

Researchers Find Less Invasive Treatment for Pleural Mesothelioma Shortens Hospital Stays, Reduces Complications, Baron and Budd Reports Talc Pleurodesis Offers Several Benefits Over Video-Assisted Method of Reducing Fluid Buildup in Lungs DALLAS – July 10 – Researchers in the United Kingdom have found that a procedure that uses talc to help seal the lining of the lungs in patients suffering from pleural mesothelioma is superior to a video-assisted surgical procedure in reducing hospital stays and the occurrence of complications, the mesothelioma law firm of Baron and Budd reports. The results of the research were published in the June 14 issue of The Lancet, a British medical journal. (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60418-9/abstract) A method of treatment known as Video-Assisted Thoracoscopic Partial Pleurectomy (VATPP) is used in some instances in order to reduce the amount of fluid buildup that takes place between the layers of lung lining in pleural mesothelioma patients. However, the researchers showed that a different procedure, one known as talc pleurodesis, can be significantly more effective. The talc pleurodesis procedure involves draining lung lining of fluid and then using talc to seal the pleural layers. The team studied 175 pleural mesothelioma patients between 2003 and 2012 who had a buildup of fluid (also known as pleural effusions) in the lungs. Of those patients, 88 had the talc pleurodesis procedure and 87 had the VATPP procedure performed. According to the study, 24 of the VATPP patients suffered surgical complications, while complications occurred in only 10 of those patients who had the talc pleurodesis procedure performed. In addition, the study showed that VATPP patients had more air leaks in their lungs and also suffered other respiratory complications. The research a lso showed that VATPP patients stayed in the hospital two times longer than talc pleurodesis patients; seven days versus three days. The survival rate of those treated with the two procedures was relatively negligible, however; 52 percent of VATPP patients survived one year after the procedure while 57 of the talc pleurodesis patients had survived. “This study is significant in the fact that it could lead to more widespread acceptance of the talc pleurodesis method, which could make pleural mesothelioma patients significantly more comfortable while undergoing treatment,” said Russell Budd, managing director of mesothelioma law firm Baron and Budd. “Taking the findings into account, as well as considering the fact that talc pleurodesis is less expensive than VATPP, it appears that talc pleurodesis is the preferable option.” There is a chance that you or a loved one who suffers from mesothelioma m ay be able to take legal action against those parties that caused the exposure to asbestos that led to the development of the disease. If you would like to learn more, call the mesothelioma law firm of Baron and Budd at 1-866-855-1229 or visit our website at http://www.fightmesothelioma.com. Contact Information Amanda Billo Baron & Budd http://baronandbudd.com +1 (214) 991-1051

Posted in News | Comments Off on Less Invasive Treatment for Pleural Mesothelioma
-->